E determination of the plasma CEP-18770 concentration of rifampicin used a validated liquid chromatography with UV detection methods. The LIQ and ULOQ were 0.10 mcg / ml and 10 mcg / ml, the inter-assay coefficients of variation and inter-assay were 89.7% to 106% and 4.14% of up to 10.5%. 2.3.3.2. Study 2. As a study, analysis of serum samples for E2, E1 and E1-S was provided by PPD Development, and the analysis of serum samples for DNG concentrations available was provided by the sponsor of the study. Methods used and the method for determining sensitivities DNG, E2, E1 and E1 S have been described above. They also analyzed to determine the plasma concentration of ketoconazole and erythromycin were performed by SFBC Anapharm and used LC-MS / MS methods validated for both ketoconazole and erythromycin LLOQs 20 ng / mL. The details and inter-assay coefficients of variation were for inter-assay ketoconazole and erythromycin be 96.1% and 112% 4.00% 6.88% and 99.7% to 107% and 1.71% 3 19%. 2.3.4. 2.3.4.1 Pharmacokinetic variables. Study 1 The most important variables are the ratio Ratios of the AUC of the serum concentration time between 0 and 24 h and the maximum serum concentration of E2 and DNG study on day 17 and 11 Secondary Re variables were AUC and Cmax of E1 and E1 S, time to Cmax of E2, DNG, E1 and E1-S and rifampicin exposure. 2.3.4.2. Study 2. The most important variables are the ratio Ratios of AUC and Cmax of E2 and DNG study on days 7 and 14 Secondary Re variables were AUC and Cmax of S E1 and E1, E2 and T max, DNG, E1 and E1 p 2.3.5. Pharmacokinetic data in both studies, pharmacokinetic studies on individual serum concentrations of E2, DNG, E1 and E1 p based Cmax and tmax were read directly on the concentration profiles of time, and the AUC was calculated using commercially Ltlichen software Studies conducted in North America and one in Europe and Australia. Both studies used a strict definition of treatment success, which has not been used previously, based on a series of strict criteria, the eight women were required to meet in order to have a complete remission. To define more precisely the reduction in menstrual blood loss with E2V/DNG and its safety profile over a gr Ere Bev And Wide Range of lkerung Invalid Women, a pooled analysis of two randomized, controlled Achieved by placebo controlled, double-blind study was conducted. However, these results are comparable to other published data, we again analyzed the combined data from these two studies using a definition of successful treatment in another recent randomized controlled Lee, the efficacy and safety compared with the levonorgestrel intrauterine system oral medroxyprogesterone acetate in women with HMB. Successful treatment in this study as less than 80 ml of MBL with an MBL Erm FINISH defined by 50% compared to baseline. Similar efficacy endpoints were evaluated in a study by Luke et al. which examined the efficacy and safety of an oral formulation of Tranexams acid for the treatment of HMB. Our analysis shows, therefore, indirectly, erm Resembled it Physicians to compare the effectiveness of the reduction in the LNG IUS compared with HMB E2V/DNG, medroxyprogesterone acetate, oral and oral.